Advertisement
Canada markets closed
  • S&P/TSX

    22,200.79
    -145.97 (-0.65%)
     
  • S&P 500

    5,267.84
    -39.17 (-0.74%)
     
  • DOW

    39,065.26
    -605.78 (-1.53%)
     
  • CAD/USD

    0.7284
    -0.0021 (-0.29%)
     
  • CRUDE OIL

    76.93
    +0.06 (+0.08%)
     
  • Bitcoin CAD

    92,815.40
    -2,052.74 (-2.16%)
     
  • CMC Crypto 200

    1,468.31
    -34.35 (-2.28%)
     
  • GOLD FUTURES

    2,333.30
    -3.90 (-0.17%)
     
  • RUSSELL 2000

    2,048.41
    -33.30 (-1.60%)
     
  • 10-Yr Bond

    4.4750
    +0.0410 (+0.92%)
     
  • NASDAQ futures

    18,691.25
    -5.00 (-0.03%)
     
  • VOLATILITY

    12.77
    +0.48 (+3.91%)
     
  • FTSE

    8,339.23
    -31.10 (-0.37%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • CAD/EUR

    0.6733
    -0.0012 (-0.18%)
     

Utah Medical Products (NASDAQ:UTMD) Has Announced A Dividend Of $0.30

Utah Medical Products, Inc.'s (NASDAQ:UTMD) investors are due to receive a payment of $0.30 per share on 5th of July. This payment means that the dividend yield will be 1.7%, which is around the industry average.

Check out our latest analysis for Utah Medical Products

Utah Medical Products' Earnings Easily Cover The Distributions

We aren't too impressed by dividend yields unless they can be sustained over time. However, prior to this announcement, Utah Medical Products' dividend was comfortably covered by both cash flow and earnings. This means that most of what the business earns is being used to help it grow.

ADVERTISEMENT

Looking forward, EPS could fall by 0.7% if the company can't turn things around from the last few years. Assuming the dividend continues along recent trends, we believe the payout ratio could be 27%, which we are pretty comfortable with and we think is feasible on an earnings basis.

historic-dividend
historic-dividend

Utah Medical Products Has A Solid Track Record

The company has been paying a dividend for a long time, and it has been quite stable which gives us confidence in the future dividend potential. The dividend has gone from an annual total of $0.98 in 2014 to the most recent total annual payment of $1.20. This works out to be a compound annual growth rate (CAGR) of approximately 2.0% a year over that time. Slow and steady dividend growth might not sound that exciting, but dividends have been stable for ten years, which we think makes this a fairly attractive offer.

Dividend Growth May Be Hard To Achieve

The company's investors will be pleased to have been receiving dividend income for some time. However, initial appearances might be deceiving. Although it's important to note that Utah Medical Products' earnings per share has basically not grown from where it was five years ago, which could erode the purchasing power of the dividend over time.

Our Thoughts On Utah Medical Products' Dividend

In summary, we are pleased with the dividend remaining consistent, and we think there is a good chance of this continuing in the future. While the payments look sustainable for now, earnings have been shrinking so the dividend could come under pressure in the future. The dividend looks okay, but there have been some issues in the past, so we would be a little bit cautious.

Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. You can also discover whether shareholders are aligned with insider interests by checking our visualisation of insider shareholdings and trades in Utah Medical Products stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.